The Procter & Gamble Company (PG)[Tv]

Key Developments

• Procter & Gamble (PG) announced a $3.8 billion acquisition of Thorne HealthTech, marking a transformative strategic pivot into the high-growth, science-backed wellness market—signaling a bold move to reposition from a stagnant consumer staple into a modern wellness innovator.
• PG’s CEO, Shailesh Jejurikar, executed an unexplained insider sale of 6,176 shares for $888,047, raising serious investor concern amid persistent stock underperformance and a widening gap with peers like Coca-Cola and Colgate-Palmolive.
• PG revealed its FY2027 shareholder return plan of $15 billion in dividends and buybacks, fully funded by $2.8 billion in productivity savings from Supply Chain 3.0 and AI-driven efficiency—demonstrating financial discipline but also highlighting a reliance on cost-cutting over organic growth.
• PG successfully challenged Quanovate’s marketing claims on its fertility monitor, leading to the company’s voluntary withdrawal of assertions—showcasing PG’s aggressive use of legal and regulatory influence in the competitive consumer health tech space.
• PG’s Q2 earnings report beat margins and free cash flow but missed revenue forecasts and issued tepid full-year EPS guidance, triggering a 2.3% post-earnings decline and reinforcing skepticism about the company’s long-term growth trajectory.